New immune therapy shows promise in kidney cancer
Agent benefits melanoma and lung cancer as well
2012-06-05
(Press-News.org) BOSTON – An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.
The results of an expanded Phase 1 trial presented at the American Society of Clinical Oncology's annual conference in Chicago, showed that some patients treated with a fully human monoclonal antibody developed by Bristol Myers Squibb had a positive response to the effort by the agent, BMS-936558, to prolong the immune system's efforts to fight off renal cell carcinoma without some of the debilitating side effects common to earlier immunotherapies.
The presentation by David F. McDermott, MD, Director of Biologic Therapy Program at the Beth Israel Deaconess Medical Center Cancer Center and an Assistant Professor of Medicine at Harvard Medical School, highlights one of two key efforts underway to use the body's own disease-fighting tools against cancer.
Separate work by David Avigan MD, Director of BIDMC's Blood/Bone Marrow Transplant Program, focuses on developing a personalized vaccine, compromised of the patient's tumor and immune system agents, to battle kidney cancer.
Cancer cells have the ability to trick the immune system, the body's self-defense mechanism, which is designed to ward off infections. Immune therapy such as antibody treatment and vaccines is designed to reeducate the body to recognized cancer as an invader.
"We've known for a long time that in certain cases the immune system can be boosted in a way that can create remissions" of hematologic malignancies like leukemia and lymphoma, says McDermott. "We've been trying to create the same long term results in solid tumors, which is more difficult."
In this trial, the antibody was designed to block the Programmed Death (PD)-1 inhibitory receptor expressed by activated T cells. PD-1 acts a natural shut off valve for T cells. By blocking its action, these cells can be revived to fight cancer. In the initial portion of the trial, the agent showed "promising" activity in patients with various solid tumors, including metastatic renal cell carcinoma, melanoma and lung cancer.
In an expanded trial, patients received up 10 mg/kg of an intravenous treatment twice weekly, followed by 1 mg/kg. Patients received up to 12 cycles of treatment until either progressive disease, unacceptable toxicity or a complete response was detected.
"These antibodies were developed based on an understanding of how the immune system is not well designed to fight cancer," says McDermott. "Your immune system is in place to help fight off infections. So when you have a viral infection, it will turn on in response to that infection and once it's controlled will shut down. The shut off valves, like PD-1, are actually stronger the pathways that turn on the immune system and this makes cancer difficult to control. The new PD-1 blocking antibody prevents this natural shutoff and allows T-cells to recognize and kill tumors."
McDermott noted that unlike current immunotherapies using interleukin-2, patients do not need to be hospitalized and suffer far less significant side effects such as skin rash or nausea.
"We realized that we could this drug at the highest doses without developing many significant or too dangerous side effects," says McDermott. "Once we realized the drug was relatively safe to give, we expanded into larger numbers of patients who seem to be benefiting early on from this treatment."
McDermott cautions that it is too early in a Phase I trial, designed principally to test side effects and the best dosage and schedule of treatment, to draw sweeping conclusions from the results.
"We have seen about 30 percent of the patients with kidney cancer have major responses to this line of treatment. A similar 30 percent of melanoma patients have had major response to treatment and there are much more melanoma patients in this study than kidney cancer patients. And maybe 20 percent or so of patients with lung cancer have had major benefit."
INFORMATION:
In addition to McDermott, authors include Charles G. Drake, Mario Sznol, Toni K. Choueiri, John Powderly, David C. Smith, Jon Wigginton, Dan McDonald, Georgia Kollia, Ashok Kumar Gupta, and Michael B. Atkins with affiliations that include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Yale Cancer Center, New Haven, CT; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston; Carolina Bio-Oncology Institute, Huntersville, NC; University of Michigan, Ann Arbor, MI; Bristol-Myers Squibb, Princeton, NJ.
McDermott serves in an advisory role with Bristol Myers Squibb, which provided funding for the study.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and currently ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-06-05
Menlo Park, Calif. — Scientists studying neutrinos have found with the highest degree of sensitivity yet that these mysterious particles behave like other elementary particles at the quantum level. The results shed light on the mass and other properties of the neutrino and prove the effectiveness of a new instrument that will yield even greater discoveries in this area.
The Enriched Xenon Observatory 200 (EXO-200), an international collaboration led by Stanford University and the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory, has begun one of ...
2012-06-05
New University of Cincinnati research has found that fewer parents in the United States vaccinated their children in the wake of concerns about a purported link (now widely discredited) between the MMR (measles, mumps, rubella) vaccine and autism.
Lenisa Chang, assistant professor of economics in UC's Carl H. Lindner College of Business, found that the MMR-autism controversy, which played out prominently in the popular media following publication in a 1998 medical journal, led to a decline of about two percentage points in terms of parents obtaining the MMR vaccine for ...
2012-06-05
PASADENA, Calif.—In the biggest result of its kind in more than ten years, physicists have made the most sensitive measurements yet in a decades-long hunt for a hypothetical and rare process involving the radioactive decay of atomic nuclei.
If discovered, the researchers say, this process could have profound implications for how scientists understand the fundamental laws of physics and help solve some of the universe's biggest mysteries—including why there is more matter than antimatter and, therefore, why regular matter like planets, stars, and humans exists at all. ...
2012-06-05
Physicians can reduce the number of heart failure deaths and unnecessary hospital admissions by using a new computer-based algorithm developed at the Institute for Clinical Evaluative Sciences (ICES) that calculates each patient's individual risk of death. Published in the Annals of Internal Medicine, the algorithm improves upon clinical decision-making and determines whether or not a patient with heart failure should be admitted to hospital. To bring this tool into the emergency departments, Peter Munk Cardiac Centre cardiologists are developing smartphone and web-based ...
2012-06-05
MATERIALS – Transparent performance . . .
Windshields, windows, solar panels, eyeglasses, heart stents and hundreds of other products representing a multi-billion-dollar market are potential targets for Oak Ridge National Laboratory's thin-film superhydrophobic technology. Conventional commercially available products tend to lack transparency, suitable bonding capability or both, making them largely impractical, said Tolga Aytug, one of the developers. The ORNL product, based on glass, can be produced with manufacturing processes that are cost effective and easily scaled ...
2012-06-05
DURHAM, N.C. -- Treating adolescents for major depression can also reduce their chances of abusing drugs later on, a secondary benefit found in a five-year study of nearly 200 youths at 11 sites across the United States.
Only 10 percent of 192 adolescents whose depression receded after 12 weeks of treatment later abused drugs, compared to 25 percent of those for whom treatment did not work, according to research led by John Curry, a professor of psychology and neuroscience at Duke University.
"It turned out that whatever they responded to -- cognitive behavioral therapy, ...
2012-06-05
Reston, Va. (June 4, 2012) – For those with esophageal cancer, initial staging of the disease is of particular importance as it determines whether to opt for a curative treatment or palliative treatment. Research presented in the June issue of The Journal of Nuclear Medicine shows that physicians using positron emission tomography (PET)/computed tomography (CT) can discern incremental staging information about the cancer, which can significantly impact management plans.
In 2012, an estimated 17,500 people will be diagnosed with esophageal cancer and 15,000 will die from ...
2012-06-05
Researchers at the University of Toronto Scarborough (UTSC) used an innovative technique to examine chemical interactions that are implicated in Parkinson's Disease.
The work details how a protein called alpha-synuclein interacting with the brain chemical dopamine can lead to protein misfolding and neuronal death.
Parkinson's Disease is a neurodegenerative disease which results in loss of motor control and cognitive function. Although the cause isn't known precisely, the disease involves the death of brain cells that produce dopamine, a chemical important in neuronal ...
2012-06-05
Tampa, Fla. (June 4, 2012) – After carrying out a study comparing the repopulation efficiency of immature hepatic stem/progenitor cells and mature hepatocytes transplanted into liver-injured rats, a research team from Sapporo, Japan concluded that mature hepatocytes offered better repopulation efficiency than stem/progenitor cells.
Until day 14 post-transplantation, the growth of the stem/progenitor cells was faster than the mature hepatocytes, but after two weeks most of the stem/progenitor cells had died. However, the mature hepatocytes continued to survive and proliferate ...
2012-06-05
Tampa, Fla. (June 4, 2012) – When autologous (self-donated) lung-derived mensenchymal stem cells (LMSCs) were transplanted endoscopically into 13 adult female sheep modeled with emphysema, post-transplant evaluation showed evidence of tissue regeneration with increased blood perfusion and extra cellular matrix content. Researchers concluded that their approach could represent a practical alternative to conventional stem cell-based therapy for treating emphysema.
The study is published in Cell Transplantation (21:1), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.
...
LAST 30 PRESS RELEASES:
[Press-News.org] New immune therapy shows promise in kidney cancer
Agent benefits melanoma and lung cancer as well
